Real World Insights: Bispecific Antibodies in R/R MM : Episode 4

Strategies For Management of Infections

December 20, 2024

By Douglas Sborov, MD, MS
Mary Steinbach, NP

Opinion

Video

Panelists discuss how any patient receiving a bispecific antibody should be given IVIG for their hypogammaglobulinemia and patients should be treated with this monthly for the first 6 months of treatment.

EP: 1.Meet a 76-Year-Old Patient With Late-Line R/R MM, Unsuitable For CAR T Therapy

EP: 2.Role of Step-Up Dosing

EP: 3.Dosing Frequency, and Adverse Event Management With Bispecific Therapy

Now Viewing

EP: 4.Strategies For Management of Infections

EP: 5.Optimizing Treatment Goals and Supportive Care For Relapsed/Refractory Multiple Myeloma in Older Patients

EP: 6.Meet a 55-Year-Old Who Was Refractory to or Relapsed on BCMA CAR T Therapy

EP: 7.Patient Tolerability of Talquetamab and Use of IVIG

EP: 8.Strategizing Talquetamab Use In Relapsed/Refractory Multiple Myeloma: Balancing Efficacy, Infection Control, and Next-Line Therapy

EP: 9.Meet our 61-Year-Old Patient With Late-Line R/R on a BCMA-Targeting Bispecific

EP: 10.Dosing Strategies in Different Targets Bispecifics

EP: 11.Managing CNS and Systemic Responses In R/R MM: Monitoring and Sequencing Strategies with Elranatamab and Cilta-Cel

EP: 12.Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

Video content above is prompted by the following:

What are we doing to help mitigate these infections and the possibility that the patient may be getting sick?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!